Editas Medicine, Inc. EDIT R2K

Healthcare · Biotechnology · United States

https://www.editasmedicine.com

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Market & Price

Market Cap

$530.98M

Current Price

$3.46

High / Low (52W)

$4.15 / $1.66

Beta

2.14

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$0.04

Price to Book

76.89

P/S

13.72

EV/EBITDA

-2.73

Dividend Yield

Profitability & Returns

ROCE

-109.70%

ROE

ROA

-26.95%

Profit Margin

Op Margin

EPS (Latest Qtr)

$-0.26

EPS (TTM)

$-1.14

Balance Sheet & Liquidity

Debt/Equity

3.92

Quick Ratio

3.17

Current Ratio

3.22

Debt

$17.30M

Total Assets

$186.53M

Current Assets

$163.90M

Working Capital

$117.65M

Ownership

Promoter Holding

0.18%

Chg in Prom Hold

FII / Inst Holding

32.02%

Chg in FII Hold

0.00%

Financial Snapshot

Enterprise Value

$232.40M

Total Revenue (TTM)

$38.69M

EBITDA

$-85.19M

Free Cash Flow

$-73.82M

Operating Cash Flow

$-140.50M

Shares Outstanding

153.46M

Gross Margin

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

27.15%

Profit 5Y

9.13%

Revenue (YoY)

-39.20%

Earnings (YoY)

PROS

Compounding revenue at 27.1% over 5 years.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	EDIT Editas Medicine, Inc. R2K	3.46	-	$530.98M	-	-109.70%	-	27.15%	9.13%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	3.93M	7.37M	14.52M	6.12M	2.07M	2.33M	3.85M	12.28M	5.72M	10.75M	62.84M	11.42M	6.50M	379.00K	6.20M	6.77M	6.36M	42.00K	9.85M	2.89M	5.34M	1.14M	513.00K	61.00K	4.66M	3.58M	7.54M	24.74M	2.83M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	39.97M	29.04M	32.09M	38.76M	27.83M
Operating Income	-10.40M	-7.38M	-	-17.84M	-19.20M	-21.16M	-	-30.63M	-26.11M	-26.75M	-	-31.56M	-39.66M	-16.26M	-26.25M	-31.26M	-35.65M	-34.59M	-	-46.62M	-31.34M	8.99M	-	-56.88M	-55.40M	-39.25M	-50.75M	-54.23M	-57.52M	-50.96M	-44.09M	-50.16M	-66.99M	-71.90M	-65.67M	-35.31M	-25.46M	-24.55M	-14.02M	-25.00M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-71.95M	-49.38M	-22.00M	-5.28M	-23.43M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.22M	2.02M	2.40M	-464.00K	1.07M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-76.09M	-53.23M	-25.12M	-5.62M	-24.98M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-47.57M	-7.41M	-12.63M	-17.75M	-19.04M	-21.02M	-39.38M	-31.10M	-26.44M	-26.60M	-36.19M	-30.94M	-38.72M	-15.24M	-25.05M	-29.25M	-33.79M	-32.94M	-37.77M	-37.72M	-23.57M	7.82M	-62.50M	-56.73M	-55.26M	-39.08M	-50.52M	-53.45M	-55.73M	-49.04M	-40.29M	-45.02M	-61.95M	-67.61M	-62.14M	-76.09M	-53.23M	-25.12M	-5.62M	-24.98M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.66	-	-0.69	-0.43	0.12	-1.00	-0.86	-0.81	-0.57	-0.74	-0.78	-0.81	-0.71	-0.56	-0.55	-0.76	-0.82	-0.75	-0.92	-0.63	-0.28	-0.06	-0.26
R&D Expense	7.28M	3.85M	-	8.88M	10.43M	10.83M	-	19.02M	17.32M	20.40M	-	21.30M	32.72M	17.44M	-	15.84M	23.57M	22.70M	-	34.57M	28.01M	33.92M	-	41.94M	33.75M	29.27M	37.98M	43.66M	41.33M	37.80M	29.78M	40.51M	48.79M	54.21M	47.64M	26.59M	16.18M	19.77M	-	17.60M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	13.73M	31.94M	20.53M	90.73M	-	19.71M	78.12M	32.31M	40.52M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	245.66M	247.30M	271.23M	139.86M
Operating Income	-12.72M	-35.31M	-97.19M	-119.93M	-113.73M	-140.92M	-134.84M	-	-225.95M	-169.18M	-238.92M	-99.34M
EBITDA	-	-	-	-	-	-	-	-	-219.61M	-163.12M	-229.09M	-148.61M
Interest Expense	-	-	-	-	-	-	-	-	-	-	2.19M	6.17M
Pretax Income	-	-	-	-	-	-	-	-	-220.43M	-153.22M	-237.09M	-160.06M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-13.69M	-72.90M	-97.18M	-120.32M	-109.95M	-133.75M	-115.98M	-	-220.43M	-153.22M	-237.09M	-160.06M
Diluted EPS	-	-	-	-	-	-2.68	-1.98	-2.85	-3.21	-2.02	-2.88	-
R&D Expense	5.07M	18.85M	56.98M	83.16M	90.65M	96.90M	158.00M	142.51M	174.96M	177.65M	199.25M	89.95M

Compounded Sales Growth

5 Years:	27.15%
1 Year:	-39.20%

Compounded Profit Growth

5 Years:	9.13%
1 Year:	-

Stock Price Performance

1 Year:	+101.16%
6 Months:	+44.77%
3 Months:	+57.27%
1 Month:	+22.70%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	149.36M	229.18M	373.26M	420.39M	508.88M	572.60M	-	514.32M	499.15M	341.59M	186.53M
Current Assets	-	-	-	-	-	-	-	-	-	356.75M	340.83M	289.31M	163.90M
Cash & Equivalents	2.01M	10.62M	143.18M	185.32M	146.63M	134.78M	238.18M	139.68M	-	141.52M	123.65M	131.54M	146.65M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	5.14M	10.19M	16.27M	15.18M
Total Liabilities	-	-	32.56M	94.58M	165.18M	184.22M	246.45M	179.02M	-	153.64M	150.06M	207.31M	159.25M
Current Liabilities	-	-	6.92M	33.08M	36.71M	35.90M	59.96M	58.21M	-	60.11M	63.22M	77.22M	46.25M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	43.95M	36.54M	35.03M	18.10M
Total Equity	-1.76M	-15.29M	-83.11M	134.61M	208.08M	236.16M	262.44M	393.59M	-	360.68M	349.10M	134.27M	27.29M
Shares Outstanding	-	-	-	-	-	-	-	-	-	68.85M	81.77M	82.73M	97.87M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-5.44M	-50.25M	-9.42M	-45.71M	-40.67M	-179.84M	-	-177.35M	-132.18M	-210.28M	-165.24M
Investing Cash Flow	-	-1.43M	-3.47M	-183.81M	-53.09M	12.25M	-140.52M	-	114.07M	-3.73M	162.15M	138.67M
Financing Cash Flow	-	139.39M	97.16M	154.53M	86.94M	131.82M	224.12M	-	1.28M	118.04M	56.03M	40.47M
Capital Expenditure	-1.22M	-1.43M	-3.49M	-2.06M	-4.75M	-6.17M	-7.16M	-	-4.12M	-4.72M	-8.83M	-607.00K
Free Cash Flow	-	-6.87M	-53.74M	-11.48M	-50.46M	-46.84M	-187.00M	-	-181.47M	-136.90M	-219.11M	-165.85M
Net Change in Cash	-	-	-	-	-	-	-	-	-62.00M	-17.87M	7.89M	13.90M

Ratios (Annual)

Figures in %.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-873.6%	-356.1%	-686.4%	-148.6%	-	-1,146.3%	-216.6%	-739.4%	-245.2%
Net Margin %	-	-	-	-876.5%	-344.3%	-651.4%	-127.8%	-	-1,118.3%	-196.1%	-733.7%	-395.0%
ROE %	89.5%	87.7%	-72.2%	-57.8%	-46.6%	-51.0%	-29.5%	-	-61.1%	-43.9%	-176.6%	-586.6%
ROCE %	-	-24.8%	-49.6%	-35.6%	-29.6%	-31.4%	-26.2%	-	-49.7%	-38.8%	-90.4%	-70.8%

Shareholding Pattern

Insiders

0.18%

Institutions

32.02%

Public Float

32.07%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	9.46%	9.26M	$32.05M
2	Vanguard Capital Management LLC	4.29%	4.20M	$14.55M
3	Renaissance Technologies, LLC	4.06%	3.97M	$13.74M
4	Vanguard Portfolio Management LLC	3.22%	3.15M	$10.89M
5	Geode Capital Management, LLC	2.36%	2.31M	$8.00M
6	State Street Corporation	2.12%	2.08M	$7.18M
7	Nuveen, LLC	2.02%	1.98M	$6.84M
8	JPMORGAN CHASE & CO	1.99%	1.95M	$6.74M
9	Shaw D.E. & Co., Inc.	1.99%	1.94M	$6.73M
10	Opaleye Management Inc.	1.97%	1.93M	$6.67M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for EDIT

VentureBeat AI Mon, 19 Jan 2026

Claude Code costs up to $200 a month. Goose does the same thing for free.

<p>The artificial intelligence coding revolution comes with a catch: it's expensive.</p><p><a href="https://claude.com/product/claude-code">Claude Code</a>, Anthropic's terminal-based AI age…

VentureBeat AI Mon, 12 Jan 2026

Anthropic launches Cowork, a Claude Desktop agent that works in your files — no coding required

<p><a href="https://www.anthropic.com/">Anthropic</a> released <a href="https://claude.com/blog/cowork-research-preview">Cowork</a> on Monday, a new AI agent capability that extends the power of its w…

EDIT · Healthcare